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ABSTRACT
Background
Early treatment of acute HIV infection with highly active antiretroviral therapy, followed by
supervised treatment interruption (STI), has been associated with at least transient control of
viremia. However, the durability of such control remains unclear. Here we present longitudinal
follow-up of a single-arm, open-label study assessing the impact of STI in the setting of acute
HIV-1 infection.
Methods and Findings
Fourteen patients were treated during acute HIV-1 infection and subsequently subjected to
an STI protocol that required retreatment if viral load exceeded 50,000 RNA copies/ml plasma
or remained above 5,000 copies/ml for more than three consecutive weeks. Eleven of 14 (79%)
patients were able to achieve viral loads of less than 5,000 RNA copies/ml for at least 90 d
following one, two, or three interruptions of treatment. However, a gradual increase in viremia
and decline in CD4þ T cell counts was observed in most individuals. By an intention-to-treat
analysis, eight (57%), six (43%), and three (21%) of 14 patients achieved a maximal period of
control of 180, 360, and 720 d, respectively, despite augmentation of HIV-specific CD4þ and
CD8þ T cell responses. The magnitude of HIV-1-specific cellular immune responses before
treatment interruption did not predict duration of viremia control. The small sample size and
lack of concurrent untreated controls preclude assessment of possible clinical benefit despite
failure to control viremia by study criteria.
Conclusions
These data indicate that despite initial control of viremia, durable viral control to less than
5,000 RNA copies/ml plasma in patients following treated acute HIV-1 infection occurs
infrequently. Determination of whether early treatment leads to overall clinical benefit will
require a larger and randomized clinical trial. These data may be relevant to current efforts to
develop an HIV-1 vaccine designed to retard disease progression rather than prevent infection
since they indicate that durable maintenance of low-level viremia may be difficult to achieve.
Introduction
The use of highly active antiretroviral therapy (HAART) can dramatically prolong the life of
individuals infected by human immunodeﬁciency virus 1 (HIV-1) [1], but early hopes for virus
eradication have not been realized [2]. The successful use of HAART is limited by drug-related
toxicities, high costs, and drug resistance [3], factors which have led to the development of
alternative therapeutic strategies, including the use of supervised, or structured, treatment
interruption (STI). This approach, involving recurrent limited exposure to autologous virus, has
not been successful in chronic infection [4,5], but has been shown to lead to at least transient
containment of viremia after intervention in the acute phase of infection in humans and
animals exposed to AIDS-associated retroviruses [6,7,8,9].
In the present study, we performed a detailed longitudinal assessment of the impact of early
treatment followed by STIs in patients treated during acute or early HIV-1 infection. The main
hypothesis of the study was that early treatment of acute HIV-1 infection followed by STI would
lead to immune boosting and subsequent control of viremia without the need for drugs. The
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copies/ml once or above 5,000 copies for three determina-
tions separated by a week each. The early results of this trial
were previously reported, showing that ﬁve of eight patients
were able to achieve a plasma viral load of 500 copies/ml or
less at a median of 6 mo off therapy [6]. The current study
investigates the frequency and durability of control achieved
with this intervention, with follow-up to a median of 5.3 y
after infection, and with an increase in size of the cohort to
14 patients. Our results indicate that, although the majority
of patients treated in the acute phase of infection go on to
control HIV-1 to less than 5,000 RNA copies/ml plasma for at
least 6 mo off therapy, the ability to contain viremia below
this level over the long term is maintained in a minority of
patients.
Methods
Objective
The hypothesis of the study was that early treatment of
acute HIV-1 infection would confer immunologic maturation
and subsequent control of HIV-1 without the need for
ongoing drug therapy. Alternatively, if a breakthrough of
virus replication was observed, this would provide a boost in
HIV-1-speciﬁc immunity after reinstitution of antiviral
therapy. The primary endpoint was the time to viral rebound
to more than 50,000 copies/ml or viral loads above 5,000
copies/ml for three determinations separated by a week each.
The secondary objective was to correlate immunologic and
virologic parameters with any observed effects including
evolution of HIV-1-speciﬁc T helper and cytotoxic T
lymphocyte responses. The original study protocol, including
the patient consent form and the institutional review board
approval, can be found in Protocols S1–S4.
Study Population
Fourteen patients presenting with acute or early HIV-1
infection were enrolled in this study between July 1997 and
January 2000 (Table 1). Acute HIV-1 infection was deﬁned by
the presence of HIV-1 RNA in the plasma, a negative or
weakly positive HIV-1 antibody by HIV-1/2 ELISA, and the
detection of no more than three bands in an HIV-1 Western
blot; early HIV-1 infection was deﬁned by a positive ELISA
and conﬁrmation of early infection by either detuned
negative ELISA or previously known negative ELISA. All
participants in the study had symptoms compatible with the
acute retroviral syndrome and were treated with HAART
(one protease inhibitor and two nucleoside reverse tran-
scriptase inhibitors) within a median of 19 d (range, 9–33)
from the onset of symptoms. Study participants were
recruited from the Massachusetts General Hospital, the
Brigham and Women’s Hospital, and the Fenway Community
Heath Care Center in Boston. All individuals gave written
informed consent to participate, and the study was approved
by the respective institutional review boards and conducted
in accordance with the human experimentation guidelines of
the Massachusetts General Hospital.
Six of the 14 individuals were investigated in an interim
study [10]. These patients were AC-02 (AS2 in [10]), AC-05
(AS5), AC-14 (AS1), AC-15 (AS3), AC-25 (AS6), and AC-46
(AS4).
Table 1. Characteristics of the Study Participants
Number
of
STI
Cycles
Patient
a Age ELISA at
Diagnosis
Baseline Values at Initiation of Therapy Initial
Therapy
Days on
Therapy
Before
First
Treatment
Interruption
Days
from
Onset
of
Symptoms
ELISA Western Blot
Number of
Bands
CD4þ
Count
(Cells/mm
3)
HIV Viral
Load
(RNA
Copies/ml)
1 AC-10
b 30 Weak pos 20 Weak pos Pos (4 bands) 919 40,700 D4T, 3TC, IDV 582
1 AC-15 40 Neg 19 Pos Pos (5 bands) 413 27,000 AZT, 3TC, IDV 902
1 AC-45 36 Weak pos 15 Pos Pos (5 bands) 377 .750,000 AZT, 3TC, NFV 344
2 AC-02 42 Neg 15 Neg Neg NA 4.85 3 10
6 AZT, 3TC, NFV 690
2 AC-13 32 Neg 10 NA NA 667 5,500 D4T, 3TC, IDV 363
2 AC-16 34 Neg 16 Neg Neg NA 337,000 AZT, 3TC, IDV 1,096
2 AC-33 29 Neg 30 Pos Pos (4 bands) 512 26,700 D4T, 3TC, NFV 931
3 AC-14
b 44 Weak pos 33 Weak pos Pos (5 bands) 981 95,100 D4T, 3TC, IDV 389
3 AC-25
b 62 Pos 31 Pos Pos (6 bands) 314 697,000 AZT, 3TC, NFV 468
3 AC-26 44 Neg 18 Weak pos Pos (2 bands) 390 .750,000 AZT, 3TC, IDV 440
3 AC-46
b 49 Neg 22 Pos Pos (5 bands) NA 123,000 AZT, 3TC, NFV 245
4 AC-04 35 Neg NA Neg Neg NA 9.62 3 10
6 AZT, 3TC, NFV 617
4 AC-05 37 Weak pos NA Ind Ind (1 band) 289 1.1 3 10
6 AZT, 3TC, NFV 663
4 AC-06 36 Neg 9 Neg Neg 551 8.18 3 10
6 D4T, 3TC, NFV 548
a All patients were males. All individuals were White Americans except AC-45, who was Hispanic.
b ELISA and Western blot positive, but infection within 180 d from time therapy was initiated.
Ind, indetermined; NA, not applicable; neg, negative; pos, positive.
DOI: 10.1371/journal.pmed.0010036.t001
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Entry criteria included treatment with HAART before or
shortly after HIV-1 seroconversion, viral suppression on
HAART to less than 400 RNA copies/ml for 2 mo, HIV-1 viral
load at the time of entry into the study of less than 50 RNA
copies/ml, and lack of signiﬁcant mutations conferring drug
resistance [11,12]. Lymphocyte proliferative response to
recombinant HIV-1 p24 protein had to exceed a stimulation
index of ten before treatment discontinuation, and net
counts per minute had to be 800 or greater. All antiretroviral
drugs were discontinued simultaneously. After a treatment
interruption, patients were seen at least once a week for the
ﬁrst 24 wk, and then monthly, with a total of at least 30 visits
for the ﬁrst year after cessation of therapy. In the second
year, visits continued monthly. Treatment was restarted if
viral load remained above 5,000 RNA copies/ml plasma for
greater than three consecutive weeks, or was in excess of
50,000 copies/ml on any single occasion.
Human Leukocyte Antigen Typing
High- and intermediate-resolution human leukocyte anti-
gen class I typing was performed at a commercial laboratory
(Dynal Biotech, Oxford, United Kingdom) by sequence-
speciﬁc PCR as described [13].
Detection of GB Virus C RNA
GB virus C (GBV-C) RNA was detected using a two-step
nested PCR ampliﬁcation reaction from whole plasma RNA.
Brieﬂy, GBV-C RNA was extracted from plasma using the
Qiagen Viral RNA Mini Kit (Qiagen, Valencia, California,
United States) according to the manufacturer’s instructions.
Extracted RNA was reverse transcribed using the Qiagen
OneStep RT-PCR Kit and ampliﬁed by nested PCR; in both
steps primers speciﬁc for the 59 UTR of GBV-C were used, as
described previously [14].
Chemokine Receptor Genotyping
In order to analyze the chemokine receptor (CCR) 5D32
deletion polymorphism, the region spanning the 32-nt
deletion was ampliﬁed by PCR, and the two alleles were
separated by gel electrophoresis [15]. The CCR2–64I poly-
morphism was detected by PCR–restriction fragment length
polymorphism analysis as described previously [16].
Synthetic HIV-1 Peptides
We synthesized 410 synthetic peptides 15–20 amino acids
long at the Massachusetts General Hospital Peptide Core
Facility on an automated peptide synthesizer using Fmoc
technology, as described [17]. Peptides overlapped by 10
amino acids and spanned the entire HIV-1 clade B 2001
consensus sequence.
ELISPOT Assays
ELISPOT assays were carried out as described previously
[18]. Peripheral blood mononuclear cells (PBMCs) were
incubated overnight at 50,000 to 100,000 cells/well in 96-well
polyvinylidene plates that had been precoated with 0.5 lg/ml
anti-human interferon-c monoclonal antibody (Mabtech,
Stockholm, Sweden). The ﬁnal concentration of the peptide
per well was 14 lg/ml. The numbers of spots per well were
counted using an automated ELISPOT plate reader (AID
EliSpot reader system, Autoimmune Diagnostika, Strassberg,
Germany). A response was considered positive if there were
more than 50 spot-forming cells (SFCs)/10
6 PBMCs and if the
well had at least three times the mean number of SFCs in the
three control wells. The dependence of responses on CD8þT
cells was determined by measuring the depletion of CD4þ T
cellsusingtheMinimacscelldepletionsystem(MiltenyiBiotec,
Bergisch-Gladbach, Germany). When HIV-1-speciﬁc CD8þ T
cell responses were detected against adjacent peptides, and
therefore might represent targeting of the overlap region,
responses to the weaker peptide were excluded for calcu-
lationsof magnitude and breadth, as previously described [19].
Proliferation Assays
Freshly isolated PBMCs (10
5 cells) were incubated with
baculovirus-derived recombinant p24 protein (Protein Sci-
ences, Meriden, Connecticut, United States) at 5 lg/ml for 6 d
and then pulsed with
3H thymidine at 1.0 lCi for 6 h before
harvesting as previously described [20]. A stimulation index
of ﬁve or greater was considered signiﬁcant.
Statistical Analysis
Time to failure during the different treatment interrup-
tions was assessed by Kaplan-Meier analysis. Patients who
were still controlling viremia at the time of last visit, who
failed because they restarted therapy without meeting the
criteria of virologic failure, or who were lost in follow-up
were included in the analyses, but the data were censored at
the last evaluable time point. Equality of survival distribu-
tions for the ﬁrst and second treatment discontinuations
was evaluated using the Wilcoxon matched-pairs signed-
ranks test. CD4þ T cell losses were calculated on regression
lines based on least squares ﬁt. A Cox proportional hazards
regression model was used for the analysis of continuous
variables such as days following onset of symptoms, CD4þ T
cell count, HIV viral load, and time to rebound of viremia,
as well as for the estimation of hazard ratios for the
categorical variables of ELISA, Western Blot, coreceptor
polymorphism, and GBV-C status. Statistical analyses of
CD8þ and CD4þ T cell responses were based on a Student’s t
test, a multiparametric ANOVA test, a Wilcoxon matched-
pairs signed-ranks test, or a Mann-Whitney U test, as
indicated. p-values lower than 0.05 were considered to
indicate statistical signiﬁcance, and all reported p-values are
two-sided. Statistical analysis and graphical presentation
were performed using SPSS, SAS, and Prism software
packages.
Table 2. Period of Viral Control Achieved Off Therapy
Duration of Viral Control (Days) Number of Patients
90 11/14
180 8/14
270 7/14
360 6/14
540 5/14
.720 3/14
DOI: 10.1371/journal.pmed.0010036.t002
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Longitudinal Assessment of Control of Viremia following
Treated Acute or Early Infection
Fourteen patients identiﬁed at the time of acute or early
infection (Table 1; Figure 1) were entered into this protocol,
and they were followed for a median of 5.3 y from the time of
infection (range, 494–2,475 d). Patients underwent successive
treatment interruptions after an initial treatment period of
at least 8 mo (median, 508 d; range, 245–1,096 d) and were
required to restart therapy when viral load exceeded 50,000
RNA copies/ml plasma on a single occasion, or 5,000 copies/
ml for three consecutive weeks. For purposes of analysis,
patients who dropped out of the study or who reinitiated
therapy without meeting criteria were considered to have lost
the ability to contain viremia.
Using these criteria for reinitiation of therapy and to
deﬁne failure, 11 of 14 patients (79%) were able to achieve
virologic control to less than 5,000 RNA copies/ml plasma for
at least 90 d after one, two, or three treatment interruptions
(Table 2). The period of longest containment was after one
interruption for ﬁve patients, after two interruptions for
eight patients, and after three interruptions for one patient
(Table 3).
Once control was achieved, the majority of the patients
experienced a subsequent rise in viremia. The median time
betweencessationoftherapyandreboundofviremia(havinga
viral load greater than 50 copies/ml) was 17 d (range, 7–169 d).
Six of 14 patients (43%) achieved a period of control after
stopping therapy for 1 y, but only three of 14 (21%) were able
to control viremia off therapy at less than 5,000 RNA copies/
ml plasma for more than 2 y. Duration of viremia control
during successive treatment interruptions was highly variable,
and there was no increase in the sustainability of viral
containment during successive STI cycles. The three patients
achieving control of viremia for more than 2 y did so during
the ﬁrst (AC-10), the second (AC-02), and the third (AC-14)
treatment interruption, respectively (Figure 2A). A paired
comparison (Wilcoxon matched-pairs signed-ranks test)
showed no signiﬁcant difference in the length of viremia
control with subsequent treatment interruptions. Although
patients experienced rebound viremia with discontinuation
of therapy, none of the patients experienced recurrence of
symptoms associated with acute HIV-1 infection.
These data show that at least transient control of viremia to
less than 5,000 RNA copies/ml plasma was achieved in the
majority of study participants during at least one of the
treatment interruptions, but that durable viral control in
participants following treated acute infection occurred
infrequently. Moreover, the data do not show a consistent
Table 3. Time to Failure during the STIs
Patient Number of STI Cycles Time to Failure or Last Follow-Up (Days)
a
First STI Second STI Third STI
AC-10 1 1,346
b
AC-15 1 666
AC-45 1 71
AC-02 2 10 1,351
b
AC-13 2 90
c 270
c
AC-16 2 561 35
AC-33 2 366 222
AC-14 3 35 147 1,070
AC-25 3 35 49 37
AC-26 3 35 47 42
AC-46 3 104 158 96
AC-04 4 50 167 37
AC-05 4 21 121
c 45
AC-06 4 61 310
d 21
Median (range) 66 (10–1,346) 158 (35–1,351) 42 (21–1,070)
a Numbers correspond to time until virological failure, unless otherwise specified.
Red indicates the longest time off therapy until failure or last follow-up.
b Last follow-up visit; patients still meeting criteria of virological control.
c Failure because patient restarted antiviral therapy without meeting criteria of virological failure.
d Virological failure due to HIV-1 superinfection.
DOI: 10.1371/journal.pmed.0010036.t003
Figure 1. HIV-1 Viral Loads and CD4þ T Cell Counts in the 14 Study Participants
Time zero corresponds to ﬁrst institution of highly active antiretroviral therapy (HAART). Closed squares, HIV-1 plasma viral loads; open
circles, CD4þ T cell counts; shaded areas, treatment with HAART according to protocol; diagonally shaded areas, patient restarted therapy
without meeting criteria of virological failure; vertical dotted lines, virological failure without reinstitution of HAART. Patients are ordered by
increasing number of supervised treatment interruptions.
DOI: 10.1371/journal.pmed.0010036.g001
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treatment interruptions.
Effect of Treatment Interruptions on CD4þ T Cell Counts
Although viral load is a strong predictor of disease
progression, CD4þ T cell loss is an additional, independent
predictor [21]. Early treatment of acute HIV-1 infection led
to normalization of CD4þ T cell counts in most patients
(median, 753 cells/mm
3; range, 492–986), but the effect of
treatment interruption was variable, even in those doing well,
as deﬁned by sustained low viral loads. Overall, 11 of 14
patients interrupted therapy for at least 12 mo, and these
Figure 2. Evolution of Viral Load and CD4þ T Cell Counts during STI
(A) Survival curves of time to virologic failure during the ﬁrst three supervised treatment interruptions. Virologic failure was deﬁned as having a
viral load of greater than 5,000 copies RNA/ml plasma for 3 wk or greater than 50,000 copies once. Patients still achieving viral control at the last
visit and individuals restarting therapy without meeting criteria or lost in follow-up are censored at the last evaluable time point. The horizontal
axis represents the time off therapy since the beginning of the treatment interruption, the vertical axis corresponds to the number of patients
maintaining control of viremia. The curves for ﬁrst, second, and third STIs do not differ signiﬁcantly from each other (log-rank test, p . 0.05).
(B) Evolution of CD4þT cell counts during the longest treatment interruption. Slopes of CD4þT cell counts during the ﬁrst year of the longest
treatment interruption are shown for patients who experienced a cessation of therapy of at least 12 mo (all except AC13, AC25, and AC45),
compared to the natural decline of CD4þ T cell counts in untreated patients of the MACS cohort with early chronic HIV-1 infection (CD4þ
counts of .350 cells/mm
3). CD4þT cell losses were calculated on a regression line based on least squares ﬁt. The two groups differed signiﬁcantly
from each other (Mann-Whitney U test, p=0.02).
(C) CD4þ T cell count at intercept and CD4þ T cell slopes during the longest treatment interruption. The CD4þ T cell slopes of the same 11
patients shown in (B) and of untreated patients of the MACS cohort are represented according to the CD4þT cell count at the intercept of the
regression line based on least squares ﬁt with the vertical axis (day 0 of treatment interruption).
DOI: 10.1371/journal.pmed.0010036.g002
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interruption on CD4þT cell loss (Figure 2B and 2C). The rate
of change in CD4þ T cell counts during the ﬁrst year of the
longest period off treatment ranged from þ157 to  438 cells/
mm
3/y (median, 192). Of the three patients who did not meet
viral load criteria for restarting therapy for more than 2 y,
one (AC-02) had an increasing CD4þT cell count of 157 cells/
mm
3/y, one (AC-10) had a stable CD4þ T cell count ( 9 cells/
mm
3/y) , and one (AC-14) experienced a decline of 344 cells/
mm
3/y. Comparison with data from the Multicenter AIDS
Cohort Study (MACS) showed that the kinetics of CD4þT cell
loss was faster (Mann-Whitney U test , p=0.02) than in
untreated patients with early chronic HIV-1 infection
(average loss of  67 cells/mm
3/y in patients with a CD4þ T
cell count of more than 350 cells/mm
3 at baseline). However,
CD4þ T cell loss rate was in the same range as what has been
described after treatment interruption in chronic HIV-1
infection [22,23]. Analysis of CD4þ T cell decline during the
second year for the three individuals who controlled viremia
for more than 2 y revealed similar trends in CD4þ T cell
slopes, although they were less steep: AC-02, þ88 cells/mm
3/y;
AC-10, þ44 cells/mm
3/y; and AC-14,  110 cells/mm
3/y. When
the ﬁrst 3 mo off therapy were excluded in order to minimize
the potential effects of recent treatment on CD4þ T cell
number, the rate of change in CD4þT cell counts during the
ﬁrst year off therapy no longer differed statistically from the
MACS data (median,  207 cell/mm
3/y; range, þ119 to  699;
Mann-Whitney U test, p=0.07). A possible reason for steep
CD4þT cell slopes may be high CD4þT cell counts at time of
treatment interruption. Comparison with MACS data (Figure
2C) showed that several of the study participants still behaved
as outliers when this factor was considered. These results
indicate that periods of relative control of viremia were
associated with declining CD4þT cell counts in most patients.
Correlation of Clinical and Genetic Markers with Duration
of Viremia Control
Although the study was small, we evaluated clinical and
laboratory parameters to see if any was predictive of duration
of viral control. Analyses included clinical and laboratory
parameters at time of presentation with acute HIV-1
infection, genetic markers associated with different rates of
disease progression, and the presence or absence of GBV-C
coinfection. All patients presented with symptomatic acute
infection. Time between onset of symptoms and institution of
therapy did not affect duration of control following STI (Cox
proportional hazards regression model, p . 0.05). The
individuals who controlled viremia for a longer time either
during the ﬁrst STI or during any of the treatment
interruptions were not different from those who experienced
earlier breakthrough as measured by ELISA and Western blot
status at initiation of HAART, coreceptor polymorphisms
(CCR5delta32, CCR2 V64I), or the presence or absence of
GBV-C coinfection (Cox proportional hazards model, p .
0.05 in all comparisons; data not shown). The only parameter
that was predictive of prolonged viral control during the ﬁrst
treatment interruption was a low viremia at time of
institution of therapy (p=0.01): there was a 2.8-fold increase
in hazard per order of magnitude increase in viral load. This
factor was no longer predictive when the period of longest
control of viremia was considered. The time to rebound of
viremia (.50 copies/ml or .400 copies/ml) did not correlate
with the duration of viral control. Although 11 out of 14
individuals achieved at least transient control of viremia, and
three experienced prolonged control, none of these patients
possessed the HLA alleles B27 or B57 associated with better
disease outcome [24,25].
Relationship of Magnitude and Breadth of HIV-1-Specific
CD8þ T Cells to Duration of Viremia Control
To assess the relationship between the clinical outcome
and evolution of HIV-1-speciﬁc CD8þ T cells, we longitudi-
nally analyzed the breadth and magnitude of CD8þ T cell
responses using an interferon-c ELISPOT and a panel of 410
overlapping peptides spanning the entire HIV-1 clade B
consensus sequence. At the beginning of the ﬁrst STI, HIV-1-
speciﬁc CD8þ T cells were weak (median of 590 SFCs/10
6
PBMCs) (Figure 3A) and narrowly directed at a median of two
epitopes (Figure 3B). CD8þ T cell responses increased
signiﬁcantly (p , 0.05) during the ﬁrst off-treatment period,
reaching a median total magnitude of 2,725 SFCs/10
6 PBMCs
and targeting a median of eight epitopes, and then were
sustained when therapy was reintroduced. A further increase
in the magnitude and breadth of HIV-1-speciﬁc CD8þT cells
was observed in the subsequent off-treatment periods,
although these augmentations failed to reach statistical
signiﬁcance. The CD8þ T cell–mediated immune responses
emerging during these consecutive cycles of treatment
interruption were broadly directed, targeting all structural
and most accessory and regulatory HIV-1 gene products (data
not shown). However, the magnitude of HIV-1-speciﬁc CD8þ
T cell responses at the beginning of the ﬁrst (r=0.01, p=
0.76), second (r=0.16, p=0.54), or third (r=0.1, p=0.55)
treatment interruptions was not predictive of the time the
study participants were subsequently able to stay off therapy
according to study criteria.
The periods off treatment allowed for assessment of the
relationship between exposure to virus and evolution of
immune responses. There was a highly signiﬁcant positive
association between time until virologic failure during the
ﬁrst treatment interruption and change in the magnitude of
HIV-1-speciﬁc CD8þ T cell responses (r=0.92, p , 0.001)
(Figure 3C). Similarly, the longer a patient remained off
therapy during the second and third interruptions, the
greater the augmentation of the total magnitude of HIV-1-
speciﬁc CD8þT cell responses (r=0.83, p , 0.016; r=0.74, p
= 0.05, respectively). The increase in CD8þ T cell epitopes
targeted during the ﬁrst treatment interruption was also
linearly correlated to the duration until virological failure (r
= 0.81, p , 0.001) (Figure 3D). However, no signiﬁcant
relationship was observed between the augmentation of
epitopes targeted during the second and third treatment
pauses and the time the study participants were able to
remain off therapy in the respective treatment interruption.
These data suggest that the duration of a treatment
interruption, and therefore the duration of exposure to
plasma virus, correlates positively with the magnitude and
breadth of HIV-1-speciﬁc CD8þT cell responses that emerge
during off-therapy time periods. Yet, CD8þ T cell responses
prior to treatment interruptions were not signiﬁcantly
predictive of the duration of time that patients are able to
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study criteria.
Relationship of Magnitude of Lymphocyte Proliferative
Responses to p24 Antigen to Duration of Viremia Control
We next analyzed evolution of lymphoproliferative re-
sponses to recombinant HIV-1 p24 Gag protein in order to
assess HIV-1-speciﬁc CD4þ T cell function. Most individuals
had no detectable response at baseline prior to treatment,
consistent with prior reports of patients with acute HIV-1
infection [20]. After initiation of therapy, all individuals
generated HIV-1-speciﬁc lymphoproliferative responses (Fig-
ure 3E), which was a criterion for inclusion in the study.
During treatment interruptions, there was a variable decline
in magnitude, and comparisons between responses on the
ﬁrst day of treatment interruption and last day off therapy
did not reach statistical signiﬁcance (ﬁrst STI, p=0.72;
second, p=0.12; and third, p=0.60, respectively). These
HIV-1-speciﬁc CD4þT cell responses also tended to rise with
reinitiation of therapy, and some of them were very robust,
with stimulation indices over 50 detected in several individ-
uals (Figure 3E). Similar to CD8þ T cell responses, the
magnitude of HIV-1-speciﬁc CD4þ T helper cell responses at
the beginning of the ﬁrst (r=0.05, p=0.43) (Figure 3F),
second (r=0.16, p=0.54), or third (r=0.1, p=0.55)
treatment interruption was not statistically predictive of the
time the study participants were subsequently able to stay off
therapy according to study criteria.
Discussion
Although early treatment of acute HIV-1 infection fol-
lowed by treatment interruptions may enhance control of
viremia [6,8], the durability of this control remains unclear.
Here we analyzed the long-term impact of initiation of
antiviral therapy during acute HIV-1 infection followed by
STIs in a cohort of 14 patients. Although initial control of
viremia to less than 5,000 RNA copies/ml plasma was achieved
in the majority of the individuals studied, a gradual increase
in viremia and decline in CD4þT cell counts was observed in
Figure 3. Evolution of HIV-1-Specific CD4þ and CD8þ T Cell Responses during STI
(A–D) Magnitude and breadth of increase of HIV-speciﬁc CD8þ T cells during supervised treatment interruptions.
(A and B) Magnitude (A) and breadth (B) of HIV-speciﬁc CD8þresponses at the ﬁrst day of treatment interruption (black bars) and at the last day
off therapy (white bars). Data represent the mean and standard deviation.
(C and D) Correlation between the increase of the magnitude (C) or breadth (D) of CD8þ T cell responses and the time off therapy during the
ﬁrst treatment interruption.
(E and F) Evolution of CD4þ T helper cell responses during supervised treatment interruptions.
(E) Magnitude of CD4 T helper cell responses at baseline and at the ﬁrst day of treatment interruption (closed circles) and last day off therapy
(open circles). Horizontal bars correspond to median values. An stimulation index greater than ﬁve was considered signiﬁcant.
(F) Correlation between the magnitude of p24-speciﬁc lymphocyte proliferative responses at the beginning of the ﬁrst treatment interruption
and the time patients were able to remain off therapy during the subsequent STI.
DOI: 10.1371/journal.pmed.0010036.g003
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Durable virologic control occurred infrequently, despite the
presence of robust HIV-1-speciﬁc CD4þ and CD8þ T cell
responses detected by standard assays. Moreover, even during
periods of successful control of viremia, progressive loss of
CD4þ T cells was frequently observed. These data indicate
that although early treatment of acute and early infection is
frequently associated with transient control of viremia after
STI, ongoing low-level viral replication is associated with
ultimate virologic breakthrough in most patients.
The standard immunologic assays and virologic assess-
ments in this cohort revealed considerable heterogeneity
among the study participants, and did not show a consistent
pattern in duration of viremia control during successive
treatment interruptions. Eleven of 14 patients (79%) were
able to maintain a viral load of less than 5,000 copies/ml for at
least 90 d, but progressive loss of control ensued in the
majority of patients and only three patients (21%) were able
to maintain control for more than 2 y. These three patients
did so during the ﬁrst (AC-10), the second (AC-02), and the
third (AC-14) STI. Clinical, genetic, and immunological
parameters did not distinguish these three individuals from
the other 11 patients, nor did they predict the duration of
control following treatment interruption. Indeed, the longer
a patient was off therapy, the stronger and more broadly
directed the CD8þ T cell responses became, but these were
still not sufﬁcient to maintain prolonged control in most
patients. Although three patients did not complete the study
as initially intended (patient AC-45 withdrew from the study
after viral breakthrough on the ﬁrst STI, AC-13 restarted
therapy despite a viral load of less than 5,000 copies/ml
during both the ﬁrst and second STIs and then withdrew, and
AC-05 restarted therapy prematurely during the second STI
but then failed to control during the third STI), the results
are not substantially different if these three are censored
rather than considered to have failed to control.
Loss of viral control in this cohort occurred not only in the
presence of strong CD8þ T cell responses, but in most cases
also in the presence of virus-speciﬁc CD4þ T cell responses,
although the CD4þ T cell responses often declined during
periods of viremia. In addition, total CD4þ T cell numbers
were also monitored and declined in most patients over time,
including one of the three patients who were able to maintain
low viral loads for at least 2 y. Mechanisms leading to rapid
CD4þ T cell loss need to be further studied in future STI
trials. Other parameters including chemokine receptor poly-
morphisms [26] and GBV-C coinfection [27,28] similarly
failed to explain the different courses following treatment
interruption. The only parameter found to be associated with
longer control of viremia during the ﬁrst treatment inter-
ruption was a lower viral load at time of institution of
antiviral therapy. Given the multiplicity of comparisons
made, the true signiﬁcance of this ﬁnding is uncertain.
The reasons for progressive loss of control despite
augmentation of virus-speciﬁc CD4þ and CD8þ Tc e l l
responses remain to be deﬁned. In one individual (AC-06),
HIV-1 superinfection in the setting of strong and broadly
directed HIV-speciﬁc cellular immune responses was asso-
ciated with the loss of viral control, as previously reported
[29]. No other cases of superinfection have been identiﬁed in
these patients (data not shown). The immunologic studies
performed failed to show an association between increases in
viral load and loss of immune responses, but this may be due
to the use of the current standard IFN-c assays to quantify
immune function. Numerous studies now indicate that IFN-c
production alone is not associated with viral load [19,30,31]
but rather that functional characteristics of CD4þ and CD8þ
T cells may be better associated with viral control
[32,33,34,35]. Such studies will be important to pursue. In
particular, even a low level of viremia correlates with a low or
undetectable frequency of interleukin-2-producing HIV-1-
speciﬁc memory CD4þ T cells endowed with proliferative
capacity in vitro [36,37,38,39], thus abrogating CD4þ T cell
help crucial to maintain efﬁcacy of CD8þT cell functions. In
an interim study of a subset of six of the 14 patients presented
here (patients AC-02, AC-05, AC-14, AC-15, AC-25, and AC-
46), a fully differentiated effector phenotype of HIV-1-
speciﬁc CD8þ T cells for selected epitopes was found to be
associated with better control of viremia [10]. Other factors
that may contribute include functional defects in antigen-
speciﬁc cell-mediated immunity [35,37,40,41,42], and pro-
gressive immune escape [43,44,45]. HIV-1-speciﬁc humoral
immunity can also affect viral control after treatment
interruption [46], and viral factors including viral ﬁtness
[47,48] and infection with multiple viral variants [49] can
inﬂuence viral set point and the rate of disease progression.
Virus sequencing studies currently in progress in this cohort
indicate that viral breakthrough is associated with sequence
changes within and outside known CTL epitopes (data not
shown). Full evaluation of the relationship between immune
escape and viral breakthrough will require extensive addi-
tional analyses, including detailed analysis of responses to
autologous virus [50,51]. Assessing the changes in CD4þ and
CD8þ T cell functions over time as well as viral evolution
under immune selection pressure will be important to
evaluate immune correlates in this cohort.
These data are important in light of other recent data on
treatment interruption in both acute and chronic infection.
In chronic HIV-1 infection, STI studies showed only margin-
al, if any, improvements of HIV-1 viremia control following a
number of treatment interruptions cycles, despite at least
transient increases in HIV-1-speciﬁc CD8þ and CD4þ T cell
responses [4,5,52,53,54,55]. In the setting of infection with a
multidrug-resistant virus, this strategy may even be delete-
rious [56]. Other studies of STI after treated acute HIV-1
infection have shown limited beneﬁts [9], including recent
trials such as the PrimSTOP trial [57] and the QUEST study
[58]. However, little is known about the relationship between
scheduling of HAART and treatment interruptions and the
characteristics of viral rebound after therapy has been
discontinued.
Although durable control of viremia was not achieved, it is
noteworthy that the majority of patients were able to achieve
transient relative containment of viremia, providing ratio-
nale for future studies aimed at further enhancing immune
control. Early treatment alone should still be considered an
important therapeutic option. Therapeutic vaccinations
administered after treated acute HIV-1 infection and before
cessation of therapy have given disappointing results thus far
[9], but the availability of new and more potent immunogens
requires reassessment of this approach. Indeed, the ability to
enhance CD4þT helper cell responses in the chronic phase of
infection has been demonstrated [59], but whether this will
enhance CD8þ T cell function requires additional studies.
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modulatory drugs, including cyclosporine [60] and hydroxy-
urea [61], in combination with antiviral therapy, presumably
because of the limitation of T cell activation. Administration
of granulocyte-macrophage colony-stimulating factor
blunted the viral rebound following interruption of HAART,
and largely prevented a decrease of CD4þT cell counts in an
STI trial in chronic HIV-1 infection [62]. These additional
therapeutic interventions deserve further investigation in
future STI studies.
Although the present study shows progressive viral break-
through, it was not designed to address whether there might
be a change in set point viremia achieved or overall clinical
beneﬁt through transient early treatment of acute HIV
infection. The deﬁnition of failure chosen for this study was
a viral load of greater than 5,000 RNA copies/ml plasma,
which at the time the study was initiated corresponded to
the level of viremia at which treatment was recommended.
Larger randomized trials will be needed to determine the
potential clinical and virologic beneﬁt of approaches based
on STIs. In studies of untreated infection, there is only a 5-
fold difference in viremia separating the quartile with the
slowest disease progression from the quartile with the most
rapid progression [63], suggesting that small differences in
steady-state viremia may inﬂuence clinical outcome. In the
meantime, STI probably should be avoided outside the
setting of controlled clinical trials. The data in this study
may also be relevant to current efforts to develop a
therapeutic AIDS vaccine designed to retard disease pro-
gression rather than prevent infection, since they suggest
that durable maintenance of low-level viremia may be
difﬁcult to achieve.
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Note Added in Proof
Recent studies in persons with chronic HIV infection
treated with HAART have now shown that immunization with
whole inactivated HIV can enhance HIV-speciﬁc CD8þT cell
function as measured by the ability to proliferate in response
to viral antigens in vitro [64].
PLoS Medicine | http://www.plosmedicine.org November 2004 | Volume 1 | Issue 2 | e36 147
Viral Control in Treated Acute HIVPatient Summary
Background. Highly active antiretroviral therapy (HAART), which is used
to treat patients with HIV, can have nasty side effects and is expensive.
As a result, for the last five years scientists have been trying to determine
if it is possible to give patients breaks from taking antiretroviral drugs,
without patients’ health suffering. It is likely that such a treatment
strategy (called ‘‘supervised treatment interruption,’’ or STI) will not work
in patients who have been infected with HIV for a long time. However,
until now, the jury was out about whether STI could be of benefit to
patients who had only recently been infected with HIV. Some research
suggested that if newly infected patients had short ‘‘holidays’’ from
taking HAART, it might help to boost their immune system—which in
turn might help to keep HIV at bay.
What Did the Researchers Do and Find? The researchers studied 14
patients who had recently been infected with HIV. Patients were treated
until their viral load was below the limit of detection by using a very
sensitive method. As they were then watched after treatment
interruption, most of them were able to maintain a low, though
detectable, viral load for some time. The researchers then stopped the
treatment and carefully watched the patients over a period of up to five
years. If the number of viruses in the patients’ blood rose too high, the
researchers gave the patients HAART again until the number of viruses
fell again. In about half the patients, treatment needed to be restarted
within a year because the viruses had started becoming more numerous
in the blood. The doctors had hoped that it would take much longer for
the number of viruses to reach this level. In other words, giving patients
‘‘drug holidays’’ did not help to keep the virus at bay for long periods of
time.
What Are the Limitations of the Study? It is relatively rare for doctors
to be able to diagnose HIV shortly after an individual becomes infected
with the virus. Many people have HIV for a long time before they see a
doctor. Therefore, even if the STI strategy had worked, it would only
have been relevant to a few patients. In addition, the study was small
and preliminary, so we have to be careful about reading too much into
the results. A limitation in the study is that it did not address whether
there might be a long-term clinical benefit despite a gradual increase in
viral load.
What Does This Study Mean for Patients? It is important to remember
that this was an experimental trial—patients with HIV should not stop
taking antiretroviral drugs unless their doctor specifically tells them to do
so. Although it looks as though STI may not work in the way everyone
had hoped, these results may help scientists develop an HIV vaccine that
is designed to keep the disease at bay. Whether early treatment of acute
infection has an overall benefit in terms of time-to-development of AIDS
or need for long-term treatment after drug discontinuation will need to
be answered in larger clinical trials designed to answer these important
questions.
Resources on the Web. AIDSinfo: http://www.aidsinfo.nih.gov/
AIDSmap: http://www.aidsmap.com/
Medline Plus AIDS Information: http://www.nlm.nih.gov/medlineplus/
aids.html
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